---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-23-000280"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T23:28:22.803269+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q1 revenue $7.4M (+18% YoY); reaffirms FY2023 guidance

## Summary
- Q1 net revenue $7.4M, up 18% YoY; net loss $2.4M ($0.05 diluted) vs $2.5M loss prior year.
- U.S. Core revenue $5.7M (+15%), International Core $1.1M (+23%), Novel Therapies $0.6M (+62%).
- Gross margin 56.1% (down from 58%), but reaffirms FY margin 58-60% and exit at 60-62%.
- Reaffirms FY2023 revenue guidance $32.5-33.5M (17-20% growth); cash >$10M year-end.

## SEC filing metadata
- accession: 0001161697-23-000280
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169723000280/0001161697-23-000280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169723000280/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-23-000280
- JSON: https://secwatch.observer/filing/0001161697-23-000280.json
- Plain text: https://secwatch.observer/filing/0001161697-23-000280.txt

## Key facts
- Earnings Releases
  KORU Medical Systems, Inc. reported first quarter ended March 31, 2023 results: revenue $7.4 million, net income $2.4 million, EPS $(0.05) per diluted share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $7.4 million
  - Net income: $2.4 million
  - EPS: $(0.05) per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: of life for patients, today reported financial results for the first quarter ended March 31, 2023. Highlights: ● First quarter net revenue growth versus prior year of 18% to $7.4 million, marking the sixth consecutive quarter of double-digit growth with strength in all three businesses ● U.S. Core business growth of 15% outpacing the subcutaneous immunoglobulin
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169723000280/0001161697-23-000280-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.